Intralesional Bleomycin Sclerotherapy Use for Lymphatic Malformation – The Starship Experience
Dr Matthew Stretton, RACS-ORLHNS, New Zealand
Authors List
*Data collection is ongoing but will be completed and analysed for conference presentation or poster*
Introduction
Congenital lymphatic malformations affecting the head and neck can cause significant symptoms including life threatening airway obstruction. Historically, treatment has been surgical, which has variable efficacy and significant morbidity. Within the last 10 years there has been increasingly widespread use of intralesional bleomycin sclerotherapy with promising results reported in the literature.
The outcomes and demographics of this population in New Zealand has not previously been studied.
Aim
To report the Starship Hospital Experience and add to the growing body of literature on advanced sclerotherapy.
Method
We have performed retrospective chart review assessing the use of intralesional bleomycin for head and neck lymphatic malformation in children by our unit over the last 10 years
Results
The first demographic data for this population has been collected, outcomes of treatment with relation to age, tracheostomy status pre/post treatment, symptoms pre/post treatment, clinical effect, adverse events and appropriateness of current protocol have been collected and analysed.
If possible, statistical analyses of outcomes will be utilised, however, given the low numbers these are unlikely to be significant. Similarly, if possible, subgroup analyses by ethnicity (Maori / Pacific vs non-Maori / Pacific) if numbers are high enough for this to be meaningful.
Conclusion
Whilst we still have some final data collection and interpretation to complete, this will be the first outcomes analysis for bleomycin sclerotherapy in New Zealand.
The research once completed will be submitted for publication in the Journal of Vascular Anomalies, the affiliated journal for the International Society for the Study of Vascular Anomalies (ISSVA).
- Stretton, M., Te Whatu Ora/Starship Children's Hospital
- Toll, E., Te Whatu Ora/Starship Children's Hospital
- Buckley, B., Te Whatu Ora, Auckland Hospital
*Data collection is ongoing but will be completed and analysed for conference presentation or poster*
Introduction
Congenital lymphatic malformations affecting the head and neck can cause significant symptoms including life threatening airway obstruction. Historically, treatment has been surgical, which has variable efficacy and significant morbidity. Within the last 10 years there has been increasingly widespread use of intralesional bleomycin sclerotherapy with promising results reported in the literature.
The outcomes and demographics of this population in New Zealand has not previously been studied.
Aim
To report the Starship Hospital Experience and add to the growing body of literature on advanced sclerotherapy.
Method
We have performed retrospective chart review assessing the use of intralesional bleomycin for head and neck lymphatic malformation in children by our unit over the last 10 years
Results
The first demographic data for this population has been collected, outcomes of treatment with relation to age, tracheostomy status pre/post treatment, symptoms pre/post treatment, clinical effect, adverse events and appropriateness of current protocol have been collected and analysed.
If possible, statistical analyses of outcomes will be utilised, however, given the low numbers these are unlikely to be significant. Similarly, if possible, subgroup analyses by ethnicity (Maori / Pacific vs non-Maori / Pacific) if numbers are high enough for this to be meaningful.
Conclusion
Whilst we still have some final data collection and interpretation to complete, this will be the first outcomes analysis for bleomycin sclerotherapy in New Zealand.
The research once completed will be submitted for publication in the Journal of Vascular Anomalies, the affiliated journal for the International Society for the Study of Vascular Anomalies (ISSVA).
